What are GLP-1 Medications?
GLP-1 (glucagon-like peptide-1) receptor agonists are a class of drugs originally developed to treat type 2 diabetes (T2D). They mimic a natural hormone (GLP-1) that helps regulate blood sugar, slows gastric emptying, increases satiety, and reduces glucagon secretion. Examples include semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), tirzepatide (Mounjaro, Zepbound), etc.
Many GLP-1s are approved for:
- Improving glycemic control in T2D
- Some have additional indications (e.g. reducing cardiovascular risk in T2D, obesity / weight management) depending on the specific drug and dose
But clinicians and researchers are increasingly using GLP-1s off-label for conditions beyond their FDA (or other regulatory body) approved ones. “Off-label” means prescribing a medication for an unapproved indication, dose, population, or duration.
Off-Label Uses / Benefits: What the Evidence Suggests
Below are several areas in which GLP-1s are being used off-label, what early evidence supports, and what remains uncertain.
| Off-Label Use | Possible Benefits & Supporting Evidence | Caveats / Uncertainties |
| Obesity / Weight Loss in Non-Diabetics (beyond approved ones) | Many T2D-approved GLP-1 agonists (e.g. semaglutide, tirzepatide) produce significant weight loss even in people without diabetes. Health care providers have reported weight loss, reductions in appetite, improvements in metabolic markers. | Dose matters; approved obesity medications have specific dosing. Side effects (GI upset, etc.) can limit tolerability. Insurance often does not cover off-label use. Long-term safety for such off-label use still being established. |
| Adjunct in Type 1 Diabetes | Some studies show that in patients with Type 1 diabetes (who normally use insulin), adding a GLP-1RA can reduce HbA1c modestly, reduce total insulin requirement, and yield weight loss. For example, a UT Southwestern study of ~104 patients using GLP-1RAs for at least 90 days saw reductions in weight, HbA1c, and insulin doses. | Risk of hypoglycemia or diabetic ketoacidosis (DKA) remains; therapy must be closely monitored. Evidence is limited in size, follow-up duration; not yet a standard of care. |
| Cardiovascular Risk in Broader Populations | GLP-1s have shown cardiovascular benefits, especially in T2D with established cardiovascular disease. Off-label use is sometimes considered in non-diabetic individuals with obesity or other risk factors, hoping to reduce risk of heart attack, stroke. Physicians report such benefits in clinical experience. | More clinical trials are needed to confirm safety & efficacy in non-diabetic populations; cost, side effects, and long-term outcomes are less well established. Regulatory approval for that indication is lacking for many GLP-1s. |
| Nonalcoholic Fatty Liver Disease (NAFLD) / Metabolic Liver Disease | Some physicians report using GLP-1-RAs to help with NAFLD, given their beneficial effects on weight, insulin resistance, and metabolic syndrome components. Early studies and case reports are promising. | Quality of evidence still low (small sample sizes, short durations); hepatic safety in long term, optimal dosing not established. |
| Reducing Insulin Dose, Glycemic Variability, and Improving Metabolic Control | In certain contexts (e.g. T1D adjunctive use, or in T2D but off-label dosing / formulations), GLP-1s help smooth out glucose peaks, reduce needed insulin, reduce “hyperinsulinemia”, and may improve overall metabolic health. | Again, risk of hypoglycemia if insulin doses not properly adjusted; some GLP-1s may have side effects; individual response varies. |
| Potential in Addiction / Craving Reduction / Behavioral Disorders | Emerging reports and early research suggest GLP-1s may reduce cravings for food and possibly substances (alcohol, opioids) through central nervous system effects. Some preliminary studies or observational data suggest reduced alcohol intoxication or drug misuse among users. | Very limited data so far; mostly observational. Safety, ethical considerations, proper clinical trial evidence are needed before firm recommendations. |
| Other Metabolic / Inflammatory Conditions | Because GLP-1s improve insulin sensitivity, reduce weight, and may reduce inflammation, there is interest in their off-label use in conditions like obesity-related comorbidities, metabolic syndrome, possibly intherosclerosis risk, etc. Some clinicians are using them in patients with prediabetes or other metabolic derangements. | Off-label for these uses means less known about long term safety, side effects, cost-benefit balance. Also, insurance/reimbursement often not favorable. |
Why Off-Label Use Is Growing
- The metabolic and weight-loss effects of many GLP-1s are quite pronounced, so clinicians see benefit beyond glucose lowering.
- Some patients do not meet strict FDA-criteria for obesity therapies but might still benefit (e.g. overweight with comorbidities).
- Patient demand and media attention also push off-label use, sometimes before full evidence is in.
- In some systems, weight-loss specific GLP-1s are newer, expensive, or not covered, so providers use the diabetes-approved versions off-label.
Risks, Ethical, Regulatory, and Practical Considerations
Off-label prescribing is legal and common, but it carries responsibilities and risks:
- Safety Uncertainty: For off-label uses, long-term safety might not be fully known, especially in different populations (children, those with other diseases).
- Side Effects: GLP-1 meds commonly cause gastrointestinal side effects (nausea, vomiting, diarrhea), sometimes more severe issues.
- Insurance / Cost: Off-label uses may not be reimbursed; patient may have to pay out-of-pocket; imposes financial burden.
- Supply / Access Issues: Heavy off-label demand can strain supply, affecting people who need the drug for approved uses (e.g. T2D).
- Regulatory & Legal Risks: Prescribers must ensure they are following standard of care, documenting their decision, considering latest guidelines; misuse or inappropriate use might lead to disciplinary or legal scrutiny.
- Equity Concerns: Studies show disparities in who gets off-label prescriptions (income, geography, race/ethnicity) which can exacerbate health inequities.
What Do We Still Need to Know?
- Long-term clinical trials in off-label indications (e.g. in non-diabetic obesity, NAFLD, in addiction, etc.).
- Optimal dosing, safety profiles, and duration in those off-label settings.
- Comparative effectiveness: which GLP-1 medications work best for which off-label use.
- Better understanding of which patient characteristics predict good outcomes vs higher risk.
- Data on cost-effectiveness, insurance coverage, and access in broader populations.
Conclusion
GLP-1 receptor agonists hold promise far beyond their original approved uses, especially in metabolic disease, weight management, and possibly behavioral / addictive conditions. At Qvita Health and Wellness, we have high level knowledge on the various benefits of these revolutionary medications. Prescribing is already common in many settings, but careful clinical judgment, monitoring, and further evidence are essential to ensure benefits outweigh risks.